摘要
目的探讨原发性卵巢淋巴瘤（primary ovarian lymphonla，POL）的临床表现、诊断、治疗及预后。方法对10例POL患者的临床资料进行回顾性分析。根据AnnArbor分期法，ⅡE期2例，ⅣE期8例。，所有病例均为B细胞来源的非霍奇金淋巴瘤（non—Hodgkin’s lymphoma，NHL）。7例弥漫大B细胞淋巴瘤（diffuse large B—cell lymphoma，DLBCI．）中，1例部分呈Burkitt样分化，1例部分呈免疫母细胞分化；2例为未进一步细分的B细胞来源的NHL；1例为边缘带B细胞淋巴瘤。，10例患者均采用手术、化疗、放疗联合的综合治疗，3例患者行高剂量化疗及自体造血十细胞移植。结果中位随访期32．8个月。3例患者至随访结束时仍无病生存。中位无进展生存期（progression-free survival，PFS）为20．6个月（4．8-95．0个月），中位总生存期（overall survival，os）为33．7个月（6．8～95．0个月）。结论POL临床表现无特异性，病理类型以DLBCL为主，临床分期多为晚期，临床上均采用手术、放疗、化疗联合的综合治疗。
Objective To explore the clinical feature, diagnosis, treatment and prognosis of primary ovarian lymphoma （POL）. Method 10 eases of POL were studied retrospectively. 2 patients were staged IIE, and 8 were IVE according to Ann Arbor staging classification. Histologically, all cases were non-Hodgkin＇s lymphoma （NHL） that originated from B cell. 7 eases were diffuse large B-cell lymphoma （DLBCL）, among which 1 ease showed partial immunoblast-like differentiation and another exhibited partial Burkitt lymphoma-like differentiation; the other 2 eases were NHLs that did not specifically desiguated; and 1 case was marginal zone B-cell lymphoma. Combination of surgery, chemotherapy and radiotherapy was used for all the patients, in which 3 patients were treated with high-dose chemotherapy and autologous stem cell transplantation. Result The median follow-up period was 32. 8 months, and 3 patients were still living without relapse. The median PFS was 20. 6 months （range 4. 8-95. 0 months）, and median OS was 33.7 months （range 6.8-95.0 months）. Conclusion The clime＇a] feature of POL is not specific, most eases are DLBCL pathologically, and often in clinically advanced stage, and combined therapy is usually adopted.
出处
《癌症进展》
2014年第1期84-88,共5页
Oncology Progress
关键词
卵巢
淋巴瘤
综合治疗
Ovary
lymphoma
combined rnodality therapy
